Literature DB >> 1988509

Human T lymphotropic virus type II (HTLV-II) infection in a cohort of New York intravenous drug users: an old infection?

R F Khabbaz1, D Hartel, M Lairmore, C R Horsburgh, E E Schoenbaum, B Roberts, T M Hartley, G Friedland.   

Abstract

To identify risk factors for human T lymphotropic virus type II (HTLV-II) infection in intravenous drug users (IVDUs), participants in a longitudinal study of human immunodeficiency virus (HIV) infection in a New York methadone maintenance program were studied. Of 270 participants tested for HTLV-I/II, 21 (8%) were seropositive. Of those, 15 (71%) had HTLV-II-specific sequences by polymerase chain reaction (PCR) and 1 (5%) had both HTLV-I- and -II-specific sequences; 3 persons with indeterminate serologic results were also PCR-positive for HTLV-II. HTLV-II infection was significantly associated with older age but was not predicted by sex, race, socioeconomic status, transfusion history, or HIV infection status. Behavioral factors since 1978, such as duration and frequency of intravenous drug use, needle sharing, visits to shooting galleries, or number of sex partners, were also not associated with HTLV-II infection. These findings are in contrast with the association of these risk factors with HIV in this group and suggest that, among IVDUs, HTLV-II is an older endemic infection that is less efficiently transmitted than HIV.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988509     DOI: 10.1093/infdis/163.2.252

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Significance of indeterminate reactivity to human T-cell lymphotropic virus in western blot analysis of individuals at risk.

Authors:  F J Medrano; V Soriano; E J Calderón; C Rey; M Gutiérrez; R Bravo; M Leal; J González-Lahoz; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

2.  Primary isolation of human T-cell leukemia-lymphoma virus types I and II: use for confirming infection in seroindeterminate blood donors.

Authors:  B Hjelle; R Mills; C Goldsmith; S G Swenson; S Cyrus
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

Review 3.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

4.  Spontaneous cell proliferation is associated with poor sensitivity to glucocorticoids in patients infected with HTLV.

Authors:  R P Lopes; M Menna-Barreto; M E Bauer
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

5.  Evaluation of a recombinant human T-cell lymphotropic virus type I (HTLV-I) p21E antibody detection enzyme immunoassay as a supplementary test in HTLV-I/II antibody testing algorithms.

Authors:  T M Hartley; G E Malone; R F Khabbaz; R B Lal; J E Kaplan
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

Review 6.  The origin and evolution of human T-cell lymphotropic virus types I and II.

Authors:  Y Suzuki; T Gojobori
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

7.  Complete nucleotide sequence of an Amerindian human T-cell lymphotropic virus type II (HTLV-II) isolate: identification of a variant HTLV-II subtype b from a Guaymi Indian.

Authors:  D Pardi; W M Switzer; K G Hadlock; J E Kaplan; R B Lal; T M Folks
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Isolation and confirmation of human T-cell leukemia virus type 2 from peripheral blood mononuclear cells.

Authors:  Michael D Lairmore; Andy Montgomery
Journal:  Methods Mol Biol       Date:  2005

9.  Identification and characterization of an extended Tax protein in human T-cell lymphotropic virus type II subtype b isolates.

Authors:  D Pardi; J E Kaplan; J E Coligan; T M Folks; R B Lal
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

10.  Multiple isolates and characteristics of human T-cell leukemia virus type II.

Authors:  W W Hall; H Takahashi; C Liu; M H Kaplan; O Scheewind; S Ijichi; K Nagashima; R C Gallo
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.